Cadila Pharma expands its oncology portfolio with monoclonal antibody, Tarzed

New Delhi: Ahmedabad-based Cadila Pharmaceuticals Limited has launched Trastuzumab, with the brand name TARZED.  Tarzed is a humanized monoclonal antibody, recommended in HER2 Positive Early Breast cancer and Metastatic Breast Cancer.

According to the latest audit report of Globocan Incidences of breast cancer are highest among all types of cancers in Indian population.

In a commitment to further strengthening of its oncology portfolio, Cadila’s TARZED is available as 440 mg injection. TARZED is considered safe and more efficacious compared to conventional treatment medicines for breast cancer.

The pharma giant says that it has always been focused on making sure high-quality, affordable, and life-saving treatments are within the reach of patients.